More than 35 years of dedication to children and youth with diabetes is recognized at national conference
There are a number of stakeholders in the promotion of health and the care of people living with diabetes. The Canadian Diabetes Association (CDA) recognizes the importance of working collaboratively with these stakeholders to improve the care of those with diabetes. CDA is an organization with an existing Clinical Practice Guideline (CPG) process, complete with expert subcommittees and methodology working groups to ensure that the guidelines are comprehensive, that the evidence review is systematic, and that there is a rigorous evaluation and grading of recommendations.
Every 5 years, since 1998, the Clinical & Scientific Section of the Canadian Diabetes Association has published comprehensive, evidence-based recommendations for healthcare professionals to consider in the prevention and management of diabetes in Canada. Dr. Alice Cheng, Chair of the 2013 Clinical Practice Guidelines shares some of the important changes that have taken place in the development of the 2013 guidelines.
Dr. Buteau PhD thesis investigated the action of Glucagon-Like Peptide-1 (GLP-1). As such, GLP-1 and its analogs have been subject to intensive investigation as anti-diabetes medications. Dr. Buteau was one of the first investigators to demonstrate the effects of GLP-1 on pancreatic beta-cell proliferation and survival, revealing a previously unrecognized mode of action of this new class of anti-diabetes medications.
Maureen Clement, Chair of the Clinical & Scientific Section (C&SS), tells you about C&SS Connect—a commitment of the C&SS Executive Committee to provide quarterly updates about the people and projects that make up the C&SS.
On February 28, 2012, the US Food and Drug Administration (FDA) approved new safety label changes for the statin class of cholesterol-lowering drugs.1 These changes included a statement regarding the effect of statins on blood glucose. The FDA stated that “increases in blood sugar levels have been reported with statin use.” However, they also indicated that “the cardiovascular benefits of statins outweigh these small increased risks.”
In January 2012, the Annals of Internal Medicine published a paper by the Johns Hopkins University Evidence-Based Practice Review Center that concluded that the Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada ranks among the world’s best diabetes guidelines.
Role of Self Monitoring of Blood Glucose: Recommendations from the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Canadian Diabetes Association.